Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Core Viewpoint - Hoth Therapeutics is advancing HT-001, a therapeutic candidate aimed at alleviating dermatological side effects in cancer patients undergoing EGFR inhibitor treatments, and plans to submit an Expanded Access application to provide access to this treatment outside traditional clinical trials [1][2]. Company Overview - Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to improve patient quality of life, emphasizing a patient-centric approach in its research and development efforts [3]. Expanded Access Program - The Expanded Access Program (EAP) is designed to provide investigational treatments to patients with serious or life-threatening conditions who lack comparable treatment options, allowing Hoth Therapeutics to offer HT-001 to eligible patients while collecting data on its safety and efficacy [2]. Leadership Commitment - Robb Knie, CEO of Hoth Therapeutics, highlighted the submission of the Expanded Access application as a significant step in the company's commitment to addressing critical unmet medical needs and improving the quality of life for cancer patients [2].